

## 1<sup>st</sup> LINE Therapeutic

### Unresectable

**UCI 01-61** A Humanitarian device exemption use protocol of TheraSphere for treatment of Unresectable Hepatocellular Carcinoma (Abi-Jaoudeh)

**UCI 15-80** Phase III Comparing Pexa-Vec Followed by Sorafenib vs. Sorafenib Pts w/ HCC w/o Prior Systemic Therapy (Abi-Jaoudeh)

**UCI 15-81** Phase 1 Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Hepatocellular Carcinoma (Abi-Jaoudeh)

**UCI 16-40** An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects with Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma (Imagawa)

**UCI 17-97** A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients with Unresectable Hepatocellular Carcinoma (HIMALAYA) (Dayyani)

# LIVER CANCER

**ECOG EAY131 (MATCH)**  
Molecular Analysis for Therapy Choice (Bota)

**SWOG S1609**  
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)

## Correlative

**UCI 03-03** Immunologic Factors Affecting Outcomes in Patients with Liver Cancer (Imagawa)

**UCI 16-29\*\*** Dynamic Contrast Enhanced Magnetic Resonance Imaging as a Biomarker to Predict Response to Liver Tumor Embolization (Lam)

## 2<sup>nd</sup> LINE Therapeutic

### Unresectable or Metastatic

**UCI 16-81** Comparing trans-arterial chemoembolization outcome using cone beam CT vs. conventional fluoroscopy (Abi-Jaoudeh)

**UCI 16-94** Phase IIA Single Arm Study of Treatment of Patients with Advanced Liver Cancer with a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti-PD1 monoclonal antibody (Abi-Jaoudeh)

**UCI 17-107** A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination with Bevacizumab Compared with Sorafenib in Patients with Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (Dayyani)

**UCI 18-14\*\*** A Phase I, Open-Label, Multicenter Dose Escalation Study of RMC-4630 Monotherapy in Adult Patients with Relapsed/Refractory Solid Tumors (Ou)

**UCI 18-19\*\*** An Open-Label, Phase Ib Multicenter Study of IBI308 in Subjects with Advanced/Metastatic Solid Malignancies (Zhu)